title: Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® system.
abstract: BACKGROUND
  There is significant immunoassay cross-reactivity between everolimus and sirolimus, and their routine determination using a common method may reduce the reagent costs.
  
  
  METHODS
  In 122 blood samples from kidney (n = 30) and liver (n = 92) transplant recipients, everolimus concentrations were determined using the Abbott IMx® microparticle enzyme immunoassay (MEIA) as previously described, and the Abbott sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® system.
  
  
  RESULTS
  A high correlation coefficient (r = 0.981, p < 0.001) and a linear regression MEIA = 0.73CMIA + 0.55, with an acceptable standard error of the estimate (ma68 = 0.32 ng/mL), were obtained, indicating the transferability of the results produced by both immunoassays.
  
  
  CONCLUSIONS
  The newly-developed sirolimus CMIA assay on the Architect® platform may be a valid alternative to other immunoassays for the routine therapeutic monitoring of everolimus.
authors.affiliation: Unidad Monitorización Fármacos, Laboratorio Central, Hospital Clínico Universitario, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain.
authors.forename: Esperanza F
authors.initials: EF
authors.lastname: Hermida-Cadahia
authors.forename: J Carlos
authors.initials: JC
authors.lastname: Tutor
mesh_terms: D000068338:Everolimus; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D007166:Immunosuppressive Agents / Q000097:blood*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D049449:Luminescence; D008280:Magnetics; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus